PMID- 7740509
OWN - NLM
STAT- MEDLINE
DCOM- 19950608
LR  - 20190727
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 77
IP  - 2
DP  - 1995 Jan 15
TI  - TFPI antigen levels in normal human volunteers after intravenous and subcutaneous 
      administration of unfractionated heparin and a low molecular weight heparin.
PG  - 175-85
AB  - Tissue factor pathway inhibitor (TFPI) is an important mediator of the in vivo 
      anticoagulant/antithrombotic properties of unfractionated heparin (UFH) and low 
      molecular weight heparin (LMWH). The vascular pool of TFPI is released into the 
      circulation after intravenous and subcutaneous administration of both UFH and 
      LMWH. We have administered LMWH (Ardeparin) and UFH to normal human volunteers in 
      a dose dependent manner. Our results demonstrate that the TFPI antigen levels 
      increase upon the intravenous and subcutaneous administration of UFH and 
      Ardeparin. Because of the better bioavailability of LMWH by the subcutaneous 
      route at equigravimetric dosages, Ardeparin released more TFPI than UFH. However, 
      when given intravenously an identical release of TFPI from the vasculature has 
      been observed. The plasma concentration of TFPI was increased 0.5-2 fold when UFH 
      or Ardeparin was administered subcutaneously and was 3 fold higher when 
      administered intravenously. This profound increase in TFPI antigen levels was 
      dependent on the dosage of Ardeparin administered. This release in TFPI 
      correlates with prolongation of the Heptest clotting assay. However, it appears 
      from this study that TFPI release precedes the elevation of the Heptest clotting 
      time.
FAU - Hoppensteadt, D A
AU  - Hoppensteadt DA
AD  - Department of Pathology, Loyola University Medical Center, Maywood, IL 60153, 
      USA.
FAU - Walenga, J M
AU  - Walenga JM
FAU - Fasanella, A
AU  - Fasanella A
FAU - Jeske, W
AU  - Jeske W
FAU - Fareed, J
AU  - Fareed J
LA  - eng
PT  - Clinical Trial
PT  - Clinical Trial, Phase I
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 0 (Lipoproteins)
RN  - 0 (lipoprotein-associated coagulation inhibitor)
RN  - 9005-49-6 (Heparin)
RN  - VL0L558GCB (ardeparin)
SB  - IM
MH  - Adult
MH  - Animals
MH  - Biological Availability
MH  - Cross-Over Studies
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Endothelium, Vascular/drug effects/metabolism
MH  - Heparin/administration & dosage/pharmacokinetics/*pharmacology
MH  - Heparin, Low-Molecular-Weight/administration & 
      dosage/pharmacokinetics/*pharmacology
MH  - Humans
MH  - Injections, Intravenous
MH  - Injections, Subcutaneous
MH  - Lipoproteins/*blood
MH  - Swine
EDAT- 1995/01/15 00:00
MHDA- 1995/01/15 00:01
CRDT- 1995/01/15 00:00
PHST- 1995/01/15 00:00 [pubmed]
PHST- 1995/01/15 00:01 [medline]
PHST- 1995/01/15 00:00 [entrez]
AID - 0049-3848(95)91623-S [pii]
AID - 10.1016/0049-3848(95)91623-s [doi]
PST - ppublish
SO  - Thromb Res. 1995 Jan 15;77(2):175-85. doi: 10.1016/0049-3848(95)91623-s.